Bayer Unveils Positive Pediatric Study Results for Low-Dose MRI Contrast Agent Gadoquatrane
Bayer AG announced positive results from the QUANTI Pediatric study on its low-dose MRI contrast agent, gadoquatrane, for children. The study showed that gadoquatrane, at a reduced gadolinium dose, has similar pharmacokinetic behavior in children as in adults. These findings were presented at the RSNA annual congress. Bayer has applied for marketing authorization in several regions, including Japan, the U.S., the EU, and China. If approved, it will be the lowest dose macrocyclic gadolinium-based contrast agent available.
Bayer AG has announced results from the QUANTI Pediatric study, evaluating its investigational low-dose MRI gadolinium-based contrast agent, gadoquatrane, in children undergoing contrast-enhanced magnetic resonance imaging (MRI). The study assessed gadoquatrane at a gadolinium dose of 0.04 mmol/kg body weight, representing a 60 percent reduction compared to standard macrocyclic GBCAs. The QUANTI Pediatric study met its primary and secondary endpoints, demonstrating similar pharmacokinetic behavior in children as observed in adults. The results indicate that the diagnostic performance seen in adults can also be applied to pediatric patients. These findings were presented as late-breaking clinical trial data at the Radiological Society of North America (RSNA) annual congress held in Chicago from November 30 to December 4, 2025. Bayer has submitted marketing authorization applications for gadoquatrane in multiple markets, including Japan, the U.S., the EU, and China. If approved, gadoquatrane would be the lowest dose macrocyclic gadolinium-based contrast agent available in these regions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
